-60%

est. 2Y upside i

HealthcareSeries D+

Rank

#3388

Sector

Healthcare AI

Est. Liquidity

~3Y

Data Quality

Data: Medium

Heads down: the current $5.3B valuation implies extreme expectations (45x trailing revenue).

Last updated: July 3, 2026

Bull (10%)+60%

IPO window opens and Abridge establishes category leadership, sustaining high multiples. Exit value ~$10.6B, net of 20% dilution yields 60% upside.

Base (55%)-69%

Multiple converges to public comp range (~7.5x) as growth decelerates. Exit value ~$2.0B, net dilution yields -69%.

Bear (35%)-80%

Multiple compresses to 5x due to incumbent competition from Epic and Microsoft, and lawsuit erosion. Exit value ~$1.36B, net dilution yields -79.5%.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

1566%

Total preferred of $830M vs $5.3B valuation implies 15.7% preference overhang.

Dilution Risk

moderate

Likely further fundraising within 2 years given high burn, potential 20% dilution.

Secondary Liquidity

none

No secondary transactions observed.

Builder — 29 roles

Operations — 12 roles

Commercial — 10 roles

View all 51 open roles at Abridge →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Abridge's data — designed to show you've done your homework.

  • 1

    “How does Abridge plan to differentiate as Epic and Microsoft launch competitive products?”

  • 2

    “What is the path to profitability and how will the $830M in funding be allocated?”

  • 3

    “Given the lawsuit, what is the risk to customer acquisition and how does the company ensure compliance?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.